Cost-effectiveness of particle therapy: current evidence and future needs

被引：0
|
作者：
Pijls-Johannesma, M. [1 ]
De Ruysscher, D. [1 ]
Lambin, P. [1 ]
机构：
[1] MAASTRO Clin, Maastricht, Netherlands
来源：
EJC SUPPLEMENTS | 2007年 / 5卷 / 04期
关键词：
D O I：
10.1016/S1359-6349(07)70570-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
931
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [21] The current situation and future aspects of cost-effectiveness in chronic myeloid leukemia treatment
    Eskazan, Ahmet Emre
    Soysal, Teoman
    LEUKEMIA & LYMPHOMA, 2015, 56 (05) : 1554 - 1555
  • [22] Response to "Future costs and the future of cost-effectiveness analysis"
    Meltzer, David
    JOURNAL OF HEALTH ECONOMICS, 2008, 27 (04) : 822 - 825
  • [23] Aligning meta-regression analyses of cost-effectiveness evidence to policy makers' needs
    Nemzoff, Cassandra
    LANCET GLOBAL HEALTH, 2024, 12 (07): : e1079 - e1080
  • [24] The cost-effectiveness of biopharmaceuticals A look at the evidence
    Wilson, Andrew W.
    Neumann, Peter J.
    MABS, 2012, 4 (02) : 281 - 288
  • [25] Evidence from Cost-Effectiveness Research
    Noyes K.
    Holloway R.G.
    NeuroRX, 2004, 1 (3): : 348 - 355
  • [26] Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of the treatment of hypertension
    Johannesson, M
    Meltzer, D
    OConor, RM
    MEDICAL DECISION MAKING, 1997, 17 (04) : 382 - 389
  • [27] COST-EFFECTIVENESS OF PHARMACOLOGICAL INTERVENTIONS FOR SMOKING CESSATION: CURRENT EVIDENCE AND POLICY IMPLICATIONS
    Heredia, I
    Valencia, A.
    Bertozzi, S.
    VALUE IN HEALTH, 2009, 12 (07) : A526 - A526
  • [28] Genetic testing for warfarin initiation: A cost-effectiveness analysis based on current evidence
    Meckley, L. M.
    Gudgeon, J. M.
    Anderson, J. L.
    Williams, M. S.
    Veenstra, D. L.
    VALUE IN HEALTH, 2008, 11 (03) : A51 - A51
  • [29] Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study
    Slot, Matilde
    Rasmussen, Thomas Bojer
    Norgaard, Mette
    Larsen, Carsten Schade
    Ehlers, Lars Holger
    PHARMACOECONOMICS-OPEN, 2024, 8 (06) : 847 - 856
  • [30] COST-EFFECTIVENESS OF DABIGATRAN WITH REAL WORLD EFFECTIVENESS EVIDENCE
    de Pouvourville, G.
    Guilmet, C.
    Cohen, A. A.
    Le Dissez, C.
    Luciani, L.
    Le Lay, K.
    VALUE IN HEALTH, 2017, 20 (09) : A399 - A399
12345